TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02730351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/ Vilanterol 100 mcg/25 mcg
Description: FF/VI 100/25 mcg will be administered via ELLIPTA inhaler once daily in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 mcg
Description: FP 250mcg will be administered via DISKUS inhaler, twice daily, once in the morning and once in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo via ELLIPTA inhaler
Description: Placebo will be administered via ELLIPTA inhaler once daily in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo via DISKUS / ACCUHALER
Description: Placebo will be administered via DISKUS / ACCUHALER, twice daily, once in the morning and once in the evening
Study: NCT00620555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Description: Orally administered gabapentin
Study: NCT02789397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab (RTX) and Azathioprine (AZA)
Description: Rituximab 375 mg/m2/dose IV over 4 hours first dose, IV over 2-3 hours each subsequent dose weekly for 4 weeks at enrollment and again at months 6 and 12 for the active comparator arm Rituximab (RTX) and Azathioprine (AZA).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: IV placebo will be administered on the same schedule as Rituximab and oral placebo will be administered by mouth daily for 18 months.
Study: NCT04445363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib hydrochloride cream
Description: Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib hydrochloride cream
Description: Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib hydrochloride cream
Description: Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib hydrochloride cream
Description: Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib hydrochloride cream
Description: Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib hydrochloride cream
Description: Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose extension: Placebo
Study: NCT03248531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab in different dosages (dose 1 and 2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab in different dosages (dose 1, 2 and 3).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided matching Bimekizumab.
Study: NCT00815568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate, busulfan
Description: Fludarabine ( 30mg/m2, iv, D-7\~D-2) Busulfan (3.2mg/kg, iv, D-6\~D-3) Total body irradiation (200cGy/day, D-2,-1)
Study: NCT00276055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Docetaxel and Bevacizumab
Description: During the treatment phase, pts. will receive the drug combination of gemcitabine, docetaxel, and bevacizumab every 2 weeks for a period of 4 weeks. This 4-week period is called a cycle of treatment. The treatment consists of receiving docetaxel IV over a 60-minute period and gemcitabine IV over a 30-minute period. Pts. will then receive bevacizumab IV over a 30-minute period. Pts. will receive this treatment once every 2 weeks. Pts. will receive at least 2 cycles of treatment unless you have progression of your disease or unmanageable side effects. As long as the size of pts.'s tumor stays the same or gets smaller, pts may continue receiving treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Docetaxel and Bevacizumab
Description: During the treatment phase, pts. will receive the drug combination of gemcitabine, docetaxel, and bevacizumab every 2 weeks for a period of 4 weeks. This 4-week period is called a cycle of treatment. The treatment consists of receiving docetaxel IV over a 60-minute period and gemcitabine IV over a 30-minute period. Pts. will then receive bevacizumab IV over a 30-minute period. Pts. will receive this treatment once every 2 weeks. Pts. will receive at least 2 cycles of treatment unless you have progression of your disease or unmanageable side effects. As long as the size of pts.'s tumor stays the same or gets smaller, pts may continue receiving treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Docetaxel and Bevacizumab
Description: During the treatment phase, pts. will receive the drug combination of gemcitabine, docetaxel, and bevacizumab every 2 weeks for a period of 4 weeks. This 4-week period is called a cycle of treatment. The treatment consists of receiving docetaxel IV over a 60-minute period and gemcitabine IV over a 30-minute period. Pts. will then receive bevacizumab IV over a 30-minute period. Pts. will receive this treatment once every 2 weeks. Pts. will receive at least 2 cycles of treatment unless you have progression of your disease or unmanageable side effects. As long as the size of pts.'s tumor stays the same or gets smaller, pts may continue receiving treatment
Study: NCT03240861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-FHBG
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellular Therapy
Description: Given LV-NYESO TCR/sr39TK PBSC IV and RV-NYESO TCR PBMC IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study: NCT00921427

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vision Restoration Therapy (VRT)
Description: 30 min, twice a day, 3 days a week, 12 weeks

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Vision Restoration Therapy (VRT)
Description: 30 min, twice a day, 3 days a week, 12 weeks
Study: NCT03240861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT03926377

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bone densitometry
Description: Patients with bullous pemphigoid will benefit from bone densitometry at the initiation of treatment, at 3 months (theoretical end of the treatment of attack) and at 6 months (theoretical end of the treatment).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood test
Description: Blood test of serum calcium, phosphoremia, albumin, 25 OH vitamin D and cortisol at 8 hours to highlight possible correlations between changes in bone mineral density and phosphocalcic parameters and 8 hours cortisolemia.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: radiographs of the thoracic and lumbar spine
Description: standard radiographs of the thoracic and lumbar spine will be done at the initiation of treatment and at 6 months.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Clobetasol propionate
Description: Clobetasol propionate (Dermoval® 0,5% cream), administered for 6 months.
Study: NCT01942824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messages
Study: NCT00952861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 200 mg QD in 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matching)
Description: Placebo QD i 5 days
Study: NCT02738541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE
Description: DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO DENTRIFICE WITHOUT PROPHOSPHATE
Description: PLACEBO DENTRIFICE WITHOUT PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
Study: NCT00698438

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ex-PRESS implantation
Description: I. Mobility check of the device. II. Administration of a local or topical anesthetic. III. Preparation and coverage of the eye by conventional sterile procedures. IV. Injection of viscoelastic material into the AC through a paracenthesis. V. Creation of a scleral tunnel up to clear cornea. VI. Creation of a (5 mm) conjunctival tunnel fornix based. VII. Lifting of the conjunctiva and tenon. VIII. Formation of a 2mm scleral incision at 0.3mm depth, 1.5mm from the limbus. IX. Application of 0.5µg/ml MMC under the tunnel for one minute.~X. Penetration into the AC using a 0.65mm stiletto, inside the tunnel of the sclera-corneal junction.~XI. Implantation of the Ex-PRESSTM through that pre-incision at the sclerocorneal junction.~XII. Introducer withdrawal. XIII. Tucking the plate under the scleral tunnel, and verification of the position inside the tunnel.~XIV. Reposition the conjunctiva with 1 - 2 sutures at the limbus. XV. Closing the conjunctiva with a suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: standard trabeculectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: standard trabeculectomy
Study: NCT04129983

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drugs and Stimulation
Description: 60 cases of sudden deafness were inquired about their medical history and examined by hearing and cranial magnetic resonance. They were randomly divided into two groups and given different treatments. The hearing test was repeated every 7 days. One month and three months after the treatment, the hearing examination was reexamined.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drugs and Stimulation
Description: 60 cases of sudden deafness were inquired about their medical history and examined by hearing and cranial magnetic resonance. They were randomly divided into two groups and given different treatments. The hearing test was repeated every 7 days. One month and three months after the treatment, the hearing examination was reexamined.
Study: NCT03532698

Intervention type: DRUG
Intervention: Aspirin
Description: Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.

Intervention type: DRUG
Intervention: Osimertinib
Description: Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.

Intervention type: DRUG
Intervention: Osimertinib
Description: Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
Study: NCT03396302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: The self-applied on-line intervention will comprise a three months behavioural intervention composed by 8 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits.
Study: NCT03849664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoflavin® solution
Description: Single drip infusion of 20 ml of Cytoflavin® solution in 200 ml of 0.9%NaCl intravenously once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoflavin® enteric-coated tablet
Description: 2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: Single drip infusion of 20 ml of placebo solution in 200 ml of 0.9%NaCl intravenously once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo enteric-coated tablet
Description: 2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
Study: NCT00394329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone dipropionate
Description: Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) one puff bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Description: Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) one puff bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Description: Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Description: Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol sulfate
Description: Albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol sulfate
Description: Albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol sulfate
Description: Albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol sulfate
Description: Albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
Study: NCT00921427

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: 2 mA/min, 30 min, twice a day, 3 days a week for 12 weeks
Study: NCT03712527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injection of Platelet rich plasma
Description: The blood of the PRP patients group will be centrifuged by the nurse using the dedicated device. A single centrifugation is required to separate the red and white blood platelets and plasma. This method of centrifugation is carried out using specific kits (Mini-GPS System III, Zimmer Biomet Company). The PRP is then collected by the nurse into a syringe that will be provided to the injector physician. Duration of preparation: 20 to 25 minutes. After a standardized sterile preparation, a local anaesthesia will be performed. Then, the injector will inject a volume of 2 mL of PRP into the median portion of the suspected disc under radiographic guidance.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Injection of NaCl
Description: The placebo will be a single-dose of saline solution which corresponds to NaCl 0,9% ProAmp 10 ml (Laboratoire Aguettant). The vials will be kept at room temperature (≤ 25°C) within the local pharmacy of each centre. 2 mL of this solution will be intra-discal injected.
Study: NCT03343782

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Expanded autologous bone marrow-derived mesenchymal stem cell
Description: Collect bone marrow from lilac crest using local anaesthetic and syringe collection. Mesenchymal stem cell will be isolated, expanded and characterized in vitro under the GMP- grade procedure
Study: NCT00391807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone acetate/ethinyl estradiol
Description: one tablet per day
Study: NCT02151968

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anaesthetic Injection
Description: Local anaesthetic is injected into the eye.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Anaesthetic Injection
Description: Local anaesthetic is injected into the eye.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guidance
Description: Device: Ultrasound Machine~Peribulbar block local anaesthetic is injected into the eye with ultrasound guidance.
Study: NCT04458363

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma (CP)
Description: Once the patient meets criteria for CP infusion (severity of disease and risk factor determination and absence of exclusion criteria), an ABO compatible product will be identified. The CP dose administered will be 10mL/kg/dose (up to 2 units per dose) times two doses per patient for a total dose of 20 mL/kg. Patients will be followed for adverse events and clinical response. Research blood testing will be obtained prior to infusion (baseline) and serially weekly afterwards until clinical resolution. Patients will receive 2 doses equaling 20 mL/kg (if available) of ABO compatible CP over 24-48 hours if they do not experience grade 3-5 adverse events that are possible, probably, or definitely attributed to CP after the first dose. Patients will be followed for adverse events for a minimum of 28 days after the last infusion of CP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard COVID-19 therapies
Description: If clinical status permits, administration of additional COVID-19 therapies should be delayed 48 hours or more from CP infusion completion. Supportive care will be administered by best clinical practice.
Study: NCT02678728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion until 12 hrs of aortic cross clamp off

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: IV loading and infusion of same volume of normal saline after induction until 12 hrs of aortic cross clamp off
Study: NCT00047008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 100 mg/m\^2 intravenously on days 1, 22

Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin
Description: 100 mg/m\^2 intravenously on days 1, 22

Intervention type: RADIATION
Group type: OTHER
Intervention: Standard fractionation RT
Description: Radiation will be delivered in 2 Gy per fraction, five fractions a week. The primary tumor and clinically/radiologically involved nodes will receive 70 Gy in 7 weeks and uninvolved nodes will receive 50 Gy in 5 weeks. The anterior lower neck field will be treated with 2 Gy per fraction at 3-cm depth to a total dose of 50 Gy.
Study: NCT01671553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling group
Description: The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above message. Additional telephone follow-up counseling at 1, 2, 3 and 8-week will be made to the participants in this group.
Study: NCT00402324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 15mg, capsules, by mouth every evening, daily for minimum of one day, followed by 5-20mg, capsules, by mouth every evening, daily for remainder of study (6 weeks total).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, capsules, by mouth every evening, daily, for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: divalproex
Description: dose to maintain blood levels of 75-125 ug/mL, by mouth, twice a day, daily for 52 days (Study Period I and Study Period II).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: divalproex
Description: dose to maintain blood levels of 75-125 ug/mL, by mouth, twice a day, daily for 52 days (Study Period I and Study Period II).
Study: NCT02412189

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maintained blood pressure
Description: Norepinephrine therapy to maintain preanesthesia blood pressure
Study: NCT03909841

Intervention type: OTHER
Intervention: Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)
Description: Quality of Life using Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)

Intervention type: OTHER
Intervention: Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)
Description: Quality of Life using Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)

Intervention type: OTHER
Intervention: Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)
Description: Quality of Life using Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)
Study: NCT04496271

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RIC (Receiver in channel)- device
Description: HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIC (Receiver in channel)- device
Description: HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication
Study: NCT02124083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Histone deactylase inhibitor
Study: NCT01277991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
Study: NCT02412189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine therapy to maintain preanesthesia blood pressure
Study: NCT01670279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: up to 3mg oral dose once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: up to 3mg oral dose once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: up to 3mg oral dose once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo